Not Your Ex. Recurrence.
We used to call it manic-depressive insanity, which, while not especially polite, at least sounded like something you should probably take seriously. In 1980, we renamed it bipolar disorder¹. The neurons did not notice. Dopamine did not lower its voice. Glutamate did not suddenly become thoughtful. The syllables just became easier to say in mixed company.
This is about that illness. Not the meme version. Not the “my ex was totally bipolar” version. The actual one.
Anthony Jeselnik once said, “I’m not afraid of dying. I’m afraid of people watching me die.” Mania can feel like that: public, grand, a little too confident that gravity is optional. Mark Maron described depression as “walking into a room and forgetting why you’re there,” which may be the most concise mood disorder description ever delivered into a microphone. And Stephen Wright once said, “I’m writing a book. I’ve got the page numbers done.” The structure exists. The life force does not.
Comedians often land the diagnosis before we finish the intake.
• Year we renamed manic-depressive insanity: 1980¹
• Years neurons cared about the rename: 0
• Lifetime prevalence of bipolar spectrum disorder: 4.4 percent¹⁹
• Casual misuse of the word “bipolar”: everywhere
That gap matters because language softens things that biology does not.
It Cycles. That’s the Whole Thing.
More than a century ago, Emil Kraepelin observed something that still anchors this diagnosis². Patients returned to baseline between episodes. They did not steadily deteriorate. They cycled. He described “periodic recurrences” with recovery in between², and that single observation continues to separate mood illness from personality.
Bipolar disorder is episodic dysregulation. It is not temperament. It is not artistic temperament. It is not intensity masquerading as personality.
In Bipolar I disorder, five-year recurrence rates can approach 70 to 90 percent without maintenance treatment³. Diagnosis is frequently delayed five to ten years⁴. Nearly half of individuals with bipolar disorder will attempt suicide at some point⁵.
• Average delay to correct diagnosis: 5–10 years⁴
• Five-year recurrence without maintenance: up to 90 percent³
• Lifetime suicide attempt rate: nearly 50 percent⁵
These are not personality statistics. They are recurrence curves.
Heather Cox Richardson wrote, “History is not inevitable. It is made by people.” She was writing about democracy, but the sentence applies here as well. Episodes are not destiny. What we do between them matters. Maintenance matters. Treatment matters.
What It Looks Like in a Room
In my office, this is not abstract.
I treat someone whose episodes arrive every six or seven years like clockwork. Stable career. Stable relationships. Then sleep evaporates, ideas accelerate, confidence detaches from evidence, and the world feels rearrangeable.
George Carlin once said, “The reason I talk to myself is because I’m the only one whose answers I accept.” Mania often feels like that: certainty without peer review.
I also treat someone who lives inches from ignition. Three nights of lost sleep and the ground tilts. That person comes in for long-acting injections because vigilance is strategy, not paranoia. Both individuals have bipolar disorder. Their lived experience differs. The underlying biology does not.
Heritability estimates range from 60 to 85 percent⁶. Dopamine overshoots reward circuits. Glutamate amplifies excitation. Circadian rhythms destabilize. Ion channel function shifts⁷. In some individuals, a serotonergic antidepressant can unmask vulnerability, with switching rates reported between 10 and 40 percent depending on subtype⁸.
• Heritability estimate: up to 85 percent⁶
• Antidepressant switching risk: 10–40 percent⁸
• Nights of sleep loss that can trigger mania: sometimes 2–3
That is not sudden creativity. That is ignition.
Kay Redfield Jamison wrote, “No amount of love can cure madness or unblacken dark moods.”⁹ She also described “a particular kind of pain, elation, loneliness, and terror involved in this kind of madness.”²⁰ Love matters. It does not regulate glutamate.
The Part People Quietly Miss
Hypomania can feel extraordinary. Faster thinking. Reduced need for sleep. Connections firing so quickly they feel like revelation instead of illness. It can feel like the brain has upgraded itself.
Richard Pryor once said, “When you ain’t got no more money, you can’t be funny.” Survival changes tone. Mania feels like the opposite of scarcity. Infinite credit extended to every idea.
Some of the most driven and compelling people I know live somewhere along this spectrum. Jamison wrote, “The intensely creative individual, so often accused of being mad, has often been able to use his or her madness in the service of art.”²⁰ That observation makes people uncomfortable because it forces precision. Treatment is not about flattening a person’s mind. It is about preventing momentum from turning destructive.
• Hours of sleep during hypomania: sometimes 3–4
• Subjective confidence level: 11 out of 10
• Probability insight feels like destiny: high
The goal is not to erase brilliance. It is to prevent brilliance from mutating into catastrophe.
The most powerful sentence I hear in my office is, “I feel good. Maybe a little too good.” When someone can say that calmly, patterns interrupt before they escalate. Awareness is not weakness. It is mastery.
The Guinea Pigs and the Quiet Metal
Lithium entered psychiatry in 1949 because John Cade suspected mania might be caused by a circulating toxin. He injected guinea pigs with urine from manic patients. The animals convulsed. He blamed uric acid and used lithium salts. The guinea pigs did not die. They became calm¹⁰. He treated ten manic patients, and they improved.
Lithium remains the gold standard mood stabilizer¹¹ and the only psychiatric medication consistently shown to reduce suicide risk in bipolar disorder, with meta-analyses demonstrating approximately a 60 percent reduction compared to placebo¹².
• Year Cade published findings: 1949¹⁰
• Initial manic patients treated: 10¹⁰
• Reduction in suicide risk with lithium: approximately 60 percent¹²
Sixty percent is not a rounding error. It is structural.
The Two That Move Fast
There are only two psychiatric medications with strong evidence for rapidly reducing suicidality: lithium and ketamine.
Ketamine can reduce suicidal ideation within hours. In treatment-resistant samples, roughly 50 to 70 percent of patients demonstrate significant reduction within 24 hours¹³ ¹⁴. Most antidepressants require weeks¹⁵. Psychotherapy reduces relapse and improves functioning¹⁶, but it does not reliably silence acute suicidality by tomorrow morning.
Stephen Wright once joked, “You can’t have everything. Where would you put it?” Suicidal ideation often feels like everything collapsing into one unbearable point. Ketamine, for some patients, simply makes space. One patient told me, “It’s not that I feel happy. I just don’t feel hunted.”
• Suicide risk relative to general population: 15–20× higher⁵
• Time to antidepressant response: weeks¹⁵
• Time to ketamine response in many patients: hours¹³
When kinetics matter, waiting is not neutral.
What This Actually Is
Traditional antidepressants primarily modulate monoamines. Lithium and ketamine influence deeper signaling pathways. Lithium increases neurotrophic factors and exerts neuroprotective effects over time¹¹ ¹⁷. Ketamine enhances synaptogenesis¹⁴ ¹⁸.
Antidepressants tune chemistry. Lithium and ketamine reinforce wiring.
Bipolar I affects roughly 1 percent of the population. Bipolar II another 1 to 2 percent. The broader spectrum approaches 4.4 percent lifetime prevalence¹⁹. Nearly half will attempt suicide⁵. Ten to twenty percent in historical cohorts will die by suicide⁵.
This is not personality. It is regulation. It is circuitry interacting with stress and sleep and dopamine and glutamate and plasticity.
It is survivable, but only if we treat it as biology instead of branding.
Why I Keep Writing This
I sit with people who cycle every few years and with people who live inches from ignition. Bipolar disorder carries one of the highest suicide risks in all of psychiatry⁵. Nearly half of individuals will attempt at some point. Historical cohorts show completion rates between 10 and 20 percent⁵. That is not metaphor. It is structural risk embedded in the illness itself.
And yet it is also an illness that can be anticipated, stabilized, and managed when treated with respect.
In my practice, I often describe it as riding a bucking bronco. We live in cowboy country. No one pretends the bronco is imaginary. No one pretends it won’t buck again. The horse is powerful. It can throw you. It can break you. But if you learn its rhythm, if you recognize the shift in its shoulders before the rear, if you know when it’s about to surge, you can stay on.
You will always have the bronco.
The work is learning how not to get thrown.
As Jamison has written, creativity and madness may share oxygen. The goal is not to suffocate the oxygen. It is to build the strength to handle it. Treatment is not about sedation. It is about stability under force. Not flattening. Balance.
When someone can say, calmly and without denial, “I feel good. Maybe a little too good,” they are adjusting their grip before the next buck. That sentence is not weakness. It is skill.
This illness is cyclical. It is biological. It carries real risk.
But risk is not destiny.
And with discipline, awareness, and respect for the circuitry, the ride does not have to end in the dirt.
If you have thoughts, questions, or pushback, leave a comment. If you want to talk in person, you know where to find me.
Beautiful downtown Boulder.
Footnotes
- ¹ American Psychiatric Association. DSM-III. Washington, DC: APA; 1980.² Kraepelin E. Manic-Depressive Insanity and Paranoia. Edinburgh: E & S Livingstone; 1921.³ Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013;381:1672–1682.⁴ Hirschfeld RMA, Lewis L, Vornik LA. Delay in diagnosis of bipolar disorder. J Clin Psychiatry. 2003;64:161–174.⁵ Hawton K, Sutton L, Haw C, Sinclair J, Deeks JJ. Suicide and bipolar disorder: systematic review. J Affect Disord. 2005;87:107–120.⁶ Smoller JW, Andreassen OA, Edenberg HJ, et al. Genetic risk architecture of bipolar disorder. Nat Genet. 2019;51:793–803.⁷ Malhi GS, Bell E, Boyce P, et al. Neurobiology of bipolar disorder. Lancet Psychiatry. 2018;5:823–836.⁸ Tondo L, Baldessarini RJ, Vazquez GH. Antidepressant-associated mania in bipolar disorder. Am J Psychiatry. 2010;167:125–135.
⁹ Jamison KR. Touched with Fire. New York: Free Press; 1993.
¹⁰ Jamison KR. An Unquiet Mind. New York: Knopf; 1995.
¹¹ Goodwin FK, Jamison KR. Manic-Depressive Illness, 2nd ed. New York: Oxford University Press; 2007.
¹² Cade JFJ. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;2:349–352.
¹³ Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in prevention of suicide in mood disorders. BMJ. 2013;346:f3646.
¹⁴ Wilkinson ST, Ballard ED, Bloch MH, et al. Ketamine and suicidal ideation: meta-analysis. Am J Psychiatry. 2018;175:150–158.
¹⁵ Wilkinson ST, Sanacora G. Ketamine: rapid-acting antidepressant. Biol Psychiatry. 2019;85:651–653.
¹⁶ American Psychiatric Association. DSM-5-TR. Washington, DC: APA; 2022.
¹⁷ Cuijpers P, Karyotaki E, Weitz E, et al. Psychotherapy for depression in adults. World Psychiatry. 2013;12:137–148.
¹⁸ Slater J. Lithium: A Doctor, a Drug, and a Breakthrough. New York: Norton; 2019.
¹⁹ Duman RS, Aghajanian GK. Synaptic dysfunction in depression. Science. 2012;338:68–72.
²⁰ Merikangas KR, Akiskal HS, Angst J, et al. Lifetime prevalence of bipolar spectrum disorder. Arch Gen Psychiatry. 2007;64:543–552.
